Table 1.

Association of CD4i antibody-like ADCC or ADCC enhancement with risk of MTCT.

	Passively-acquired ADCC			Maternal ADCC
Entire cohort	Adjusted OR	95% CI	p-value	Adjusted OR	95% CI	p-value
A32-like ADCC	1.005	0.985–1.026	0.61	1.013	0.989–1.038	0.29
C11-like ADCC	0.967	0.929–1.006	0.096	0.977	0.943–1.013	0.21
Total cluster A-specific ADCC	0.995	0.977–1.013	0.60	1.001	0.982–1.021	0.90
17b-LALA-mediated enhancement	0.997	0.988–1.007	0.58	0.989	0.977–1.002	0.11
Excluding transmissions after 6 months	Adjusted OR	95% CI	p-value	Adjusted OR	95% CI	p-value
A32-like ADCC	1.003	0.979–1.029	0.80	1.016	0.988–1.045	0.26
C11-like ADCC	0.962	0.915–1.011	0.12	0.993	0.954–1.033	0.71
Total cluster A-specific ADCC	0.992	0.968–1.016	0.49	1.008	0.986–1.031	0.48
17b-LALA-mediated enhancement	0.987	0.965–1.009	0.25	0.990	0.975–1.005	0.18

The association of CD4i epitope-specific ADCC (A32-like ADCC, C11-like ADCC, or total cluster A-specific ADCC (sum of A32-like ADCC + C11-like ADCC)) and 17b-LALA-mediated enhancement of plasma ADCC with odds of MTCT was measured using a logistic regression analysis adjusted for maternal plasma viral load. Adjusted odds ratios (OR), 95% confidence intervals (CI), and p-values are shown for infant samples (passively-acquired ADCC, left) and maternal samples (maternal ADCC, right). Statistical significance was defined as p < 0·05 (*). The top rows show results from the entire cohort (71 maternal samples and 71 infant samples). The bottom rows show results from the cohort after excluding the seven mother-infant pairs in which transmission occurred after six months of age of the infant (64 maternal samples and 64 infant samples). Data from individual biological replicates from seven maternal samples and six infant samples that were below the limit of detection were excluded from the analysis as described in the Materials and Methods.